Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878617 · ClinicalTrials.gov registry record · Phase 2
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Phase 2 study of Medulloblastoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 660
- Enrollment target
- 20
- Study locations
NCT01878617 is a Phase 2 study of Medulloblastoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 660 participants, above the 118-participant average among 29 other Medulloblastoma trials with a reported enrollment target (459% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT01878617, a Phase 2 study of Medulloblastoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 660 participants
- Enrollment target
- 20
- Study locations
Study Summary
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH). This stratified clinical and molecular treatment approach will be used to evaluate the following: * To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. * To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. * To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. * To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study. All participants on this study will have surgery to remove as much of the primary tumor as safely possible, radiation therapy, and chemotherapy. The amount of radiation therapy and type of chemotherapy received will be determined by the participant's treatment stratum. Treatment stratum assignment will be based on the tumor's molecular subgroup assignment and clinical risk. The participant will be assigned to one of three medulloblastoma subgroups determined by analysis of the tumor tissue for tumor biomarkers: * WNT (Strata W): positi
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Vincristine
- DRUG Vismodegib
- RADIATION Craniospinal Irradiation with boost to the primary tumor site
Study Locations (20)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Cancer Center - Houston
California
- Lucille Packard Children's Hospital at Stanford University Medical Center - Palo Alto
- Rady Children's Hospital - San Diego
Florida
- University of Florida - Gainesville
- Arnold Palmer Hospital for Children - Orlando
New South Wales
- Sydney Children's Hospital - Randwick
- Children's Hospital at Westmead - Westmead
Connecticut
- Yale University - New Haven
District of Columbia
- Children's National Medical Center - Washington D.C.
Minnesota
- Children's Hospital and Clinics of Minnesota - Minneapolis
North Carolina
- Duke Children's Hospital and Health Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2013-06-23 |
| Est. Completion | 2031-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01878617
The ClinicalTrials.gov registry entry for NCT01878617 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 29 other Medulloblastoma trials with a reported enrollment target (459% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medulloblastoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01878617 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01878617 about?
NCT01878617 is a clinical study titled "A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma". Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment....
What is the current status of trial NCT01878617?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 660 participants. The study started on 2013-06-23. Estimated completion is 2031-10-13.
What conditions does trial NCT01878617 study?
This clinical trial studies the following conditions: Medulloblastoma.
What interventions are being tested in trial NCT01878617?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Vincristine (DRUG), Vismodegib (DRUG), Craniospinal Irradiation with boost to the primary tumor site (RADIATION).
Who is sponsoring clinical trial NCT01878617?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01878617 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
RECRUITING · Phase 2
-
Digoxin Medulloblastoma Study
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
-
Methionine PET/CT Studies In Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.